SCHEDULE: Deep Track Capital Amends Zura Bio Stake to 0.40%

Deep Track Capital, LP and affiliates have filed an amended Schedule 13G, disclosing a beneficial ownership of 0.40% in Zura Bio Ltd.'s Class A Ordinary Shares.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin collectively reported beneficial ownership of 259,014 Class A Ordinary Shares of Zura Bio Ltd.
• This ownership represents 0.40% of the total Class A Ordinary Shares outstanding.
• The reporting persons hold shared voting and dispositive power over all 259,014 shares.
• The ownership percentage is calculated based on 65,018,058 Class A Ordinary Shares outstanding as of August 4, 2025, as reported in Zura Bio Ltd.'s 10-Q filing on August 14, 2025.
• The filing is an Amendment No. 4 to a Schedule 13G, indicating a change from previous ownership disclosures.
• The reporting persons certified that the securities were not acquired and are not held for the purpose of changing or influencing control of Zura Bio Ltd.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the implied significant reduction in beneficial ownership by a specialized institutional investor, suggesting a diminished conviction in the company's prospects.

Positives

• The filing provides transparency regarding institutional ownership in Zura Bio Ltd.

Negatives

• The reported beneficial ownership of 0.40% by Deep Track Capital, LP and its affiliates, as an Amendment No. 4, implies a significant reduction in their stake, which could be interpreted as a diminished conviction in Zura Bio Ltd.'s prospects.

Future Outlook

No forward-looking statements or guidance were provided in this ownership disclosure filing.

Industry Context

Schedule 13G filings are mandatory disclosures by passive institutional investors who own less than 5% of a company's outstanding shares. This amendment indicates a change in Deep Track Capital's stake in Zura Bio Ltd., a specialized biotechnology company. Such changes in institutional ownership, especially by funds focused on specific sectors, are closely watched by the market as they can signal shifts in investor sentiment or strategic positioning within the biotechnology industry.

Stakeholder Impact

• Shareholders: A reduction in institutional ownership by a specialized fund may lead to negative market perception and potentially impact share price, signaling a lack of confidence from a sophisticated investor.

Key Dates

Recommendation

The significant reduction in beneficial ownership by Deep Track Capital, LP, a specialized biotech fund, to 0.40% of Zura Bio Ltd. indicates a diminished conviction in the company's future prospects or a strategic divestment. This move by an informed institutional investor suggests a potential negative outlook, warranting a 'sell' recommendation for other investors.

Keywords

Zura Bio Ltd, Deep Track Capital, Schedule 13G, Beneficial Ownership, Class A Ordinary Shares, Institutional Investor, Biotechnology, SEC Filing